View More View Less
  • 1 Medical Faculty, Semmelweis Medical University, Gastroenterological and Endocrinological Research Department of the Hungarian Academy of Sciences 2nd Department of Internal Medicine Szentkirályi u. 46. H-1088 Budapest Hungary
  • | 2 Medical Faculty, Semmelweis Medical University Immunological Laboratory, Department of Dermatology and Venerology Budapest Hungary
  • | 3 Diagnosticum Rt. Budapest Hungary
Restricted access

Non-alcoholic fatty liver disease (NAFLD) is developed mainly by insulin resistance and oxidative stress, but the exact pathogenesis is unknown. Increased prevalence of non-organ specific autoantibodies (NOSA) in NAFLD may be the result of primary immune-mediated mechanism or secondary hepatocellular injury as a consequence of free radical reaction and cytokine production. The importance of NOSA positivity in NAFLD is uncertain. Our aim was to investigate the NOSA prevalence and the redox status as well as the cytokine level in NAFLD patients. Plasma free SH-group concentration, total antioxidant status were measured by colorimetric methods. Free radical–antioxidant balance was determined by a chemiluminometric assay. IL-6 concentration was measured by ELISA in various group of NAFLD patients. NOSA (antinuclear antibody) prevalence was found to be 55% in NAFLD patients. NOSA-positive patients showed a decrease of plasma free SH-group concentration, total antioxidant status and strengthening of free radical reaction. Elevated IL-6 concentrations were measured in both patient groups, but IL-6 concentration was higher in the ANA-negative group with better antioxidant status.

  • Loria, P., Lonardo, A., Leonardi, F. et al.: Non-organ-specific autoantibodies in nonalcoholic fatty liver disease. Dig. Dis. Sci., 2003, 48 , 2173–2181.

    Leonardi F. , 'Non-organ-specific autoantibodies in nonalcoholic fatty liver disease ' (2003 ) 48 Dig. Dis. Sci. : 2173 -2181.

    • Search Google Scholar
  • Day, C. P.: Non-alcoholic steatohepatitis (NASH): where are we now and where we going. Gut, 2002, 50 , 585–588.

    Day C. P. , 'Non-alcoholic steatohepatitis (NASH): where are we now and where we going ' (2002 ) 50 Gut : 585 -588.

    • Search Google Scholar
  • Fehér, J., Lengyel, G.: Pathogenesis and clinics of non-alcoholic steatohepatitis. (In Hungarian). Eur. J. Gastroenterol. Hepatol., 2002, 6 , 185–191.

    Lengyel G. , 'Pathogenesis and clinics of non-alcoholic steatohepatitis. (In Hungarian) ' (2002 ) 6 Eur. J. Gastroenterol. Hepatol. : 185 -191.

    • Search Google Scholar
  • Fehér, J., Lengyel, G.: A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). J. Int. Metab. Res., 2003, 31 , 537–551.

    Lengyel G. , 'A new approach to drug therapy in non-alcoholic steatohepatitis (NASH) ' (2003 ) 31 J. Int. Metab. Res. : 537 -551.

    • Search Google Scholar
  • Adams, L. A., Lindor, K. D., Angulo, P.: The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am. J. Gastroenterol., 2004, 99 , 1316–1320.

    Angulo P. , 'The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease ' (2004 ) 99 Am. J. Gastroenterol. : 1316 -1320.

    • Search Google Scholar
  • Cotler, S. J., Kanji, K., Keshavarzian, A. et al.: Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J. Clin. Gastroenterol., 2004, 38 , 801–804.

    Keshavarzian A. , 'Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis ' (2004 ) 38 J. Clin. Gastroenterol. : 801 -804.

    • Search Google Scholar
  • Hagymási, K., Blázovics, A., Lengyel, G. et al.: Oxidative damage in alcoholic liver disease. Eur. J. Gastroenterol. Hepatol., 2001, 13 , 49–55.

    Lengyel G. , 'Oxidative damage in alcoholic liver disease ' (2001 ) 13 Eur. J. Gastroenterol. Hepatol. : 49 -55.

    • Search Google Scholar
  • Emlen, W., O’Neill, L.: Clinical significance of antinuclear antibodies. Comparison of detection with immunofluorescence and enzyme linked immunosorbent assays. Arthritis Rheum., 1997, 40 , 1612–1618.

    O’Neill L. , 'Clinical significance of antinuclear antibodies. Comparison of detection with immunofluorescence and enzyme linked immunosorbent assays ' (1997 ) 40 Arthritis Rheum. : 1612 -1618.

    • Search Google Scholar
  • Tan, E. M., Smolen, J. S., McDougal, J. S. et al.: A critical evaluation of enzyme immunoassays for detection of antinuclear antibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum., 1999, 42 , 455–464.

    McDougal J. S. , 'A critical evaluation of enzyme immunoassays for detection of antinuclear antibodies of defined specificities. I. Precision, sensitivity, and specificity ' (1999 ) 42 Arthritis Rheum. : 455 -464.

    • Search Google Scholar
  • Sedlak, J., Lindsay, R. H.: Estimation of total, protein bound and non protein sulfhydril groups in tissues with Ellmann’s reagent. Anal. Biochem., 1968, 25 , 192–205.

    Lindsay R. H. , 'Estimation of total, protein bound and non protein sulfhydril groups in tissues with Ellmann’s reagent ' (1968 ) 25 Anal. Biochem. : 192 -205.

    • Search Google Scholar
  • Blázovics, A., Kovács, Á., Lugasi, A. et al.: Antioxidant defense in erythrocytes and plasma of patients with active and quiescent Crohn’s disease and ulcerative colitis: A chemiluminescent study. Clin. Chem., 1999, 45 , 895–896.

    Lugasi A. , 'Antioxidant defense in erythrocytes and plasma of patients with active and quiescent Crohn’s disease and ulcerative colitis: A chemiluminescent study ' (1999 ) 45 Clin. Chem. : 895 -896.

    • Search Google Scholar
  • Brailly, H., Montero-Julian, F. A., Zuber, C. E. et al.: Total interleukin 6 plasma measured by immunoassay. Clin. Chem., 1994, 40 , 116–123.

    Zuber C. E. , 'Total interleukin 6 plasma measured by immunoassay ' (1994 ) 40 Clin. Chem. : 116 -123.

    • Search Google Scholar
  • Miller, N. J., Rice-Evans, C., Davies, M. J. et al.: A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin. Sci., 1993, 84 , 407–412.

    Davies M. J. , 'A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates ' (1993 ) 84 Clin. Sci. : 407 -412.

    • Search Google Scholar
  • Mashige, F., Tanaka, N., Maki, A. et al.: Direct spectrophotometry of total bile acids in serum. Clin. Chem., 1981, 27 , 1352–1356.

    Maki A. , 'Direct spectrophotometry of total bile acids in serum ' (1981 ) 27 Clin. Chem. : 1352 -1356.

    • Search Google Scholar
  • Czaja, A. J., Homburger, H. A.: Autoantibodies in liver disease. Gastroenterology, 2001, 120 , 239–249.

    Homburger H. A. , 'Autoantibodies in liver disease ' (2001 ) 120 Gastroenterology : 239 -249.

  • Czaja, A., Carpenter, H. A., Santrach, P. J. et al.: Genetic predisposition for immunological features in chronic liver diseases other than autoimmune hepatitis. J. Hepatol., 1996, 24 , 52–59.

    Santrach P. J. , 'Genetic predisposition for immunological features in chronic liver diseases other than autoimmune hepatitis ' (1996 ) 24 J. Hepatol. : 52 -59.

    • Search Google Scholar
  • McCullough, A. J.: Update on nonalcoholic fatty liver disease. J. Clin. Gastroenterol., 2002, 34 , 255–262.

    McCullough A. J. , 'Update on nonalcoholic fatty liver disease ' (2002 ) 34 J. Clin. Gastroenterol. : 255 -262.

    • Search Google Scholar
  • Sanyal, A. J.: AGA technical review on nonalcoholic fatty liver disease. Gastroenterology, 2002, 123 , 1705–1725.

    Sanyal A. J. , 'AGA technical review on nonalcoholic fatty liver disease ' (2002 ) 123 Gastroenterology : 1705 -1725.

    • Search Google Scholar
  • Farrell, G. C., Larter, C. Z.: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology, 2006, 43 (2Suppl2) , S99–S112.

    Larter C. Z. , 'Nonalcoholic fatty liver disease: from steatosis to cirrhosis ' (2006 ) 43 Hepatology : S99 -S112.

    • Search Google Scholar
  • Duvnjak, M., Lerotič, I., Barsič, N. et al.: Pathogenesis and management issues for nonalcoholic fatty liver disease. W. J. Gastroenterol., 2007, 13 , 4539–4550.

    Barsič N. , 'Pathogenesis and management issues for nonalcoholic fatty liver disease ' (2007 ) 13 W. J. Gastroenterol. : 4539 -4550.

    • Search Google Scholar
  • Tuma, D. J.: Role of malondialdehyde-acetaldehyde adducts in liver injury. Free Rad. Biol. Med., 2002, 32 , 303–308.

    Tuma D. J. , 'Role of malondialdehyde-acetaldehyde adducts in liver injury ' (2002 ) 32 Free Rad. Biol. Med. : 303 -308.

    • Search Google Scholar
  • Clot, P., Albano, E., Eliasson, E. et al.: Cytochrome P4502E1 hydroxyethyl radical adducts as the major antigen in autoantibody formation among alcoholics. Gastroenterology, 1996, 111 , 206–216.

    Eliasson E. , 'Cytochrome P4502E1 hydroxyethyl radical adducts as the major antigen in autoantibody formation among alcoholics ' (1996 ) 111 Gastroenterology : 206 -216.

    • Search Google Scholar
  • Dupont, I., Lucas, D., Clot, P. et al.: Cytochrome P4502E1 inducibility and hydroxyethyl radical formation among alcoholics. J. Hepatol., 1998, 28 , 567–571.

    Clot P. , 'Cytochrome P4502E1 inducibility and hydroxyethyl radical formation among alcoholics ' (1998 ) 28 J. Hepatol. : 567 -571.

    • Search Google Scholar
  • Torres, D. M., Harrison, S. A.: Current treatments in nonalcoholic steatohepatitis. Curr. Treat. Opt. Gastroenterol., 2007, 10 , 425–434.

    Harrison S. A. , 'Current treatments in nonalcoholic steatohepatitis ' (2007 ) 10 Curr. Treat. Opt. Gastroenterol. : 425 -434.

    • Search Google Scholar
  • Mehta, K., Van Thiel, D. H., Shah, N. et al.: Nonalcoholic fatty liver disease: pathogenesis and role of antioxidants. Nutr. Rev., 2004, 60 , 289–293.

    Shah N. , 'Nonalcoholic fatty liver disease: pathogenesis and role of antioxidants ' (2004 ) 60 Nutr. Rev. : 289 -293.

    • Search Google Scholar

Hungarian Medical Journal
Language English
Size  
Year of
Foundation
2007
Publication
Programme
ceased
Volumes
per Year
 
Issues
per Year
 
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1788-6139 (Print)
ISSN 1789-0403 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jun 2021 3 0 0
Jul 2021 3 0 0
Aug 2021 3 0 0
Sep 2021 3 2 2
Oct 2021 4 0 0
Nov 2021 2 0 0
Dec 2021 0 0 0